"targetId","targetName","comparatorId","comparatorName","outcomeId","outcomeName","type"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436070,"Vitamin D deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436070,"Vitamin D deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436070,"Vitamin D deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436070,"Vitamin D deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436070,"Vitamin D deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436070,"Vitamin D deficiency","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436070,"Vitamin D deficiency","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436070,"Vitamin D deficiency","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436070,"Vitamin D deficiency","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436070,"Vitamin D deficiency","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436070,"Vitamin D deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",318800,"Gastroesophageal reflux disease","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",318800,"Gastroesophageal reflux disease","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",318800,"Gastroesophageal reflux disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",318800,"Gastroesophageal reflux disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",318800,"Gastroesophageal reflux disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",318800,"Gastroesophageal reflux disease","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",318800,"Gastroesophageal reflux disease","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",318800,"Gastroesophageal reflux disease","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",318800,"Gastroesophageal reflux disease","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",318800,"Gastroesophageal reflux disease","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",318800,"Gastroesophageal reflux disease","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",433316,"Dizziness and giddiness","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",433316,"Dizziness and giddiness","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",433316,"Dizziness and giddiness","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",433316,"Dizziness and giddiness","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",433316,"Dizziness and giddiness","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",433316,"Dizziness and giddiness","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",433316,"Dizziness and giddiness","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",433316,"Dizziness and giddiness","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",433316,"Dizziness and giddiness","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",433316,"Dizziness and giddiness","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",433316,"Dizziness and giddiness","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201826,"Type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201826,"Type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201826,"Type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201826,"Type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201826,"Type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201826,"Type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201826,"Type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201826,"Type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201826,"Type 2 diabetes mellitus","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201826,"Type 2 diabetes mellitus","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201826,"Type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",141932,"Seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",141932,"Seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",141932,"Seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",141932,"Seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",141932,"Seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",141932,"Seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",141932,"Seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",141932,"Seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",141932,"Seborrheic keratosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",141932,"Seborrheic keratosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",141932,"Seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",138825,"Actinic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",138825,"Actinic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",138825,"Actinic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",138825,"Actinic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",138825,"Actinic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",138825,"Actinic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",138825,"Actinic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",138825,"Actinic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",138825,"Actinic keratosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",138825,"Actinic keratosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",138825,"Actinic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",313459,"Sleep apnea","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",313459,"Sleep apnea","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",313459,"Sleep apnea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",313459,"Sleep apnea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",313459,"Sleep apnea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",313459,"Sleep apnea","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",313459,"Sleep apnea","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",313459,"Sleep apnea","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",313459,"Sleep apnea","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",313459,"Sleep apnea","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",313459,"Sleep apnea","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436962,"Insomnia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436962,"Insomnia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436962,"Insomnia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436962,"Insomnia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436962,"Insomnia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436962,"Insomnia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436962,"Insomnia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436962,"Insomnia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436962,"Insomnia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436962,"Insomnia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436962,"Insomnia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",75860,"Constipation","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",75860,"Constipation","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",75860,"Constipation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",75860,"Constipation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",75860,"Constipation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",75860,"Constipation","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",75860,"Constipation","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",75860,"Constipation","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",75860,"Constipation","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",75860,"Constipation","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",75860,"Constipation","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",439082,"Menopausal syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",439082,"Menopausal syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",439082,"Menopausal syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",439082,"Menopausal syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",439082,"Menopausal syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",439082,"Menopausal syndrome","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",439082,"Menopausal syndrome","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",439082,"Menopausal syndrome","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",439082,"Menopausal syndrome","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",439082,"Menopausal syndrome","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",439082,"Menopausal syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197381,"Epigastric pain","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197381,"Epigastric pain","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197381,"Epigastric pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197381,"Epigastric pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197381,"Epigastric pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197381,"Epigastric pain","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197381,"Epigastric pain","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197381,"Epigastric pain","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197381,"Epigastric pain","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197381,"Epigastric pain","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197381,"Epigastric pain","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",136057,"Benign neoplasm of skin of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",136057,"Benign neoplasm of skin of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",136057,"Benign neoplasm of skin of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",136057,"Benign neoplasm of skin of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",136057,"Benign neoplasm of skin of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",136057,"Benign neoplasm of skin of trunk","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",136057,"Benign neoplasm of skin of trunk","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",136057,"Benign neoplasm of skin of trunk","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",136057,"Benign neoplasm of skin of trunk","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",136057,"Benign neoplasm of skin of trunk","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",136057,"Benign neoplasm of skin of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",40483107,"Inflamed seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",40483107,"Inflamed seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",40483107,"Inflamed seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",40483107,"Inflamed seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",40483107,"Inflamed seborrheic keratosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",40483107,"Inflamed seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",40483107,"Inflamed seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",40483107,"Inflamed seborrheic keratosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",40483107,"Inflamed seborrheic keratosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",40483107,"Inflamed seborrheic keratosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",40483107,"Inflamed seborrheic keratosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4193704,"Type 2 diabetes mellitus without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",432284,"Single major depressive episode","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",432284,"Single major depressive episode","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",432284,"Single major depressive episode","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",432284,"Single major depressive episode","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",432284,"Single major depressive episode","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",432284,"Single major depressive episode","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",432284,"Single major depressive episode","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",432284,"Single major depressive episode","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",432284,"Single major depressive episode","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",432284,"Single major depressive episode","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",432284,"Single major depressive episode","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",437833,"Hypokalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",437833,"Hypokalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",437833,"Hypokalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",437833,"Hypokalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",437833,"Hypokalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",437833,"Hypokalemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",437833,"Hypokalemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",437833,"Hypokalemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",437833,"Hypokalemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",437833,"Hypokalemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",437833,"Hypokalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",31317,"Dysphagia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",31317,"Dysphagia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",31317,"Dysphagia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",31317,"Dysphagia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",31317,"Dysphagia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",31317,"Dysphagia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",31317,"Dysphagia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",31317,"Dysphagia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",31317,"Dysphagia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",31317,"Dysphagia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",31317,"Dysphagia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",140641,"Verruca vulgaris","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",140641,"Verruca vulgaris","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",140641,"Verruca vulgaris","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",140641,"Verruca vulgaris","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",140641,"Verruca vulgaris","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",140641,"Verruca vulgaris","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",140641,"Verruca vulgaris","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",140641,"Verruca vulgaris","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",140641,"Verruca vulgaris","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",140641,"Verruca vulgaris","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",140641,"Verruca vulgaris","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",137351,"Epidermoid cyst of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",137351,"Epidermoid cyst of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",137351,"Epidermoid cyst of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",137351,"Epidermoid cyst of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",137351,"Epidermoid cyst of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",137351,"Epidermoid cyst of skin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",137351,"Epidermoid cyst of skin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",137351,"Epidermoid cyst of skin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",137351,"Epidermoid cyst of skin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",137351,"Epidermoid cyst of skin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",137351,"Epidermoid cyst of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",374375,"Impacted cerumen","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",374375,"Impacted cerumen","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",374375,"Impacted cerumen","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",374375,"Impacted cerumen","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",374375,"Impacted cerumen","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",374375,"Impacted cerumen","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",374375,"Impacted cerumen","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",374375,"Impacted cerumen","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",374375,"Impacted cerumen","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",374375,"Impacted cerumen","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",374375,"Impacted cerumen","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",437264,"Tobacco dependence syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",437264,"Tobacco dependence syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",437264,"Tobacco dependence syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",437264,"Tobacco dependence syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",437264,"Tobacco dependence syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",437264,"Tobacco dependence syndrome","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",437264,"Tobacco dependence syndrome","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",437264,"Tobacco dependence syndrome","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",437264,"Tobacco dependence syndrome","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",437264,"Tobacco dependence syndrome","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",437264,"Tobacco dependence syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",435796,"Dehydration","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",435796,"Dehydration","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",435796,"Dehydration","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",435796,"Dehydration","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",435796,"Dehydration","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",435796,"Dehydration","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",435796,"Dehydration","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",435796,"Dehydration","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",435796,"Dehydration","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",435796,"Dehydration","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",435796,"Dehydration","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",79864,"Hematuria syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",79864,"Hematuria syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",79864,"Hematuria syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",79864,"Hematuria syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",79864,"Hematuria syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",79864,"Hematuria syndrome","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",79864,"Hematuria syndrome","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",79864,"Hematuria syndrome","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",79864,"Hematuria syndrome","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",79864,"Hematuria syndrome","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",79864,"Hematuria syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201322,"Internal hemorrhoids without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201322,"Internal hemorrhoids without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201322,"Internal hemorrhoids without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201322,"Internal hemorrhoids without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201322,"Internal hemorrhoids without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201322,"Internal hemorrhoids without complication","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201322,"Internal hemorrhoids without complication","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201322,"Internal hemorrhoids without complication","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201322,"Internal hemorrhoids without complication","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201322,"Internal hemorrhoids without complication","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201322,"Internal hemorrhoids without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",195562,"Hemorrhoids","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",195562,"Hemorrhoids","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",195562,"Hemorrhoids","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",195562,"Hemorrhoids","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",195562,"Hemorrhoids","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",195562,"Hemorrhoids","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",195562,"Hemorrhoids","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",195562,"Hemorrhoids","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",195562,"Hemorrhoids","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",195562,"Hemorrhoids","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",195562,"Hemorrhoids","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201061,"Diaphragmatic hernia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201061,"Diaphragmatic hernia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201061,"Diaphragmatic hernia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201061,"Diaphragmatic hernia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201061,"Diaphragmatic hernia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201061,"Diaphragmatic hernia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201061,"Diaphragmatic hernia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201061,"Diaphragmatic hernia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201061,"Diaphragmatic hernia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201061,"Diaphragmatic hernia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201061,"Diaphragmatic hernia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201620,"Kidney stone","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201620,"Kidney stone","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201620,"Kidney stone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201620,"Kidney stone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201620,"Kidney stone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201620,"Kidney stone","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201620,"Kidney stone","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201620,"Kidney stone","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201620,"Kidney stone","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201620,"Kidney stone","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201620,"Kidney stone","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",434005,"Morbid obesity","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",434005,"Morbid obesity","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",434005,"Morbid obesity","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",434005,"Morbid obesity","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",434005,"Morbid obesity","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",434005,"Morbid obesity","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",434005,"Morbid obesity","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",434005,"Morbid obesity","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",434005,"Morbid obesity","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",434005,"Morbid obesity","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",434005,"Morbid obesity","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",437246,"Vitamin B deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",437246,"Vitamin B deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",437246,"Vitamin B deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",437246,"Vitamin B deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",437246,"Vitamin B deficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",437246,"Vitamin B deficiency","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",437246,"Vitamin B deficiency","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",437246,"Vitamin B deficiency","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",437246,"Vitamin B deficiency","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",437246,"Vitamin B deficiency","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",437246,"Vitamin B deficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",318736,"Migraine","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",318736,"Migraine","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",318736,"Migraine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",318736,"Migraine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",318736,"Migraine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",318736,"Migraine","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",318736,"Migraine","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",318736,"Migraine","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",318736,"Migraine","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",318736,"Migraine","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",318736,"Migraine","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",136184,"Pruritus of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",136184,"Pruritus of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",136184,"Pruritus of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",136184,"Pruritus of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",136184,"Pruritus of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",136184,"Pruritus of skin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",136184,"Pruritus of skin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",136184,"Pruritus of skin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",136184,"Pruritus of skin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",136184,"Pruritus of skin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",136184,"Pruritus of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",139099,"Ingrowing nail","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",139099,"Ingrowing nail","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",139099,"Ingrowing nail","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",139099,"Ingrowing nail","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",139099,"Ingrowing nail","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",139099,"Ingrowing nail","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",139099,"Ingrowing nail","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",139099,"Ingrowing nail","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",139099,"Ingrowing nail","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",139099,"Ingrowing nail","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",139099,"Ingrowing nail","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197610,"Cyst of ovary","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197610,"Cyst of ovary","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197610,"Cyst of ovary","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197610,"Cyst of ovary","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197610,"Cyst of ovary","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197610,"Cyst of ovary","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197610,"Cyst of ovary","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197610,"Cyst of ovary","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197610,"Cyst of ovary","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197610,"Cyst of ovary","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197610,"Cyst of ovary","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",375806,"Idiopathic peripheral neuropathy","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",375806,"Idiopathic peripheral neuropathy","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",375806,"Idiopathic peripheral neuropathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",375806,"Idiopathic peripheral neuropathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",375806,"Idiopathic peripheral neuropathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",375806,"Idiopathic peripheral neuropathy","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",375806,"Idiopathic peripheral neuropathy","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",375806,"Idiopathic peripheral neuropathy","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",375806,"Idiopathic peripheral neuropathy","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",375806,"Idiopathic peripheral neuropathy","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",375806,"Idiopathic peripheral neuropathy","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",373478,"Presbyopia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",373478,"Presbyopia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",373478,"Presbyopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",373478,"Presbyopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",373478,"Presbyopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",373478,"Presbyopia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",373478,"Presbyopia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",373478,"Presbyopia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",373478,"Presbyopia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",373478,"Presbyopia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",373478,"Presbyopia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",434613,"Generalized anxiety disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",434613,"Generalized anxiety disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",434613,"Generalized anxiety disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",434613,"Generalized anxiety disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",434613,"Generalized anxiety disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",434613,"Generalized anxiety disorder","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",434613,"Generalized anxiety disorder","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",434613,"Generalized anxiety disorder","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",434613,"Generalized anxiety disorder","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",434613,"Generalized anxiety disorder","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",434613,"Generalized anxiety disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",80824,"Senile osteoporosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",80824,"Senile osteoporosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",80824,"Senile osteoporosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",80824,"Senile osteoporosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",80824,"Senile osteoporosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",80824,"Senile osteoporosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",80824,"Senile osteoporosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",80824,"Senile osteoporosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",80824,"Senile osteoporosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",80824,"Senile osteoporosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",80824,"Senile osteoporosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",81151,"Sprain of ankle","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",81151,"Sprain of ankle","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",81151,"Sprain of ankle","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",81151,"Sprain of ankle","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",81151,"Sprain of ankle","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",81151,"Sprain of ankle","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",81151,"Sprain of ankle","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",81151,"Sprain of ankle","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",81151,"Sprain of ankle","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",81151,"Sprain of ankle","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",81151,"Sprain of ankle","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",30753,"Esophagitis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",30753,"Esophagitis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",30753,"Esophagitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",30753,"Esophagitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",30753,"Esophagitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",30753,"Esophagitis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",30753,"Esophagitis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",30753,"Esophagitis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",30753,"Esophagitis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",30753,"Esophagitis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",30753,"Esophagitis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",30234,"Neck sprain","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",30234,"Neck sprain","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",30234,"Neck sprain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",30234,"Neck sprain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",30234,"Neck sprain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",30234,"Neck sprain","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",30234,"Neck sprain","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",30234,"Neck sprain","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",30234,"Neck sprain","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",30234,"Neck sprain","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",30234,"Neck sprain","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",381877,"Dysfunction of eustachian tube","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",381877,"Dysfunction of eustachian tube","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",381877,"Dysfunction of eustachian tube","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",381877,"Dysfunction of eustachian tube","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",381877,"Dysfunction of eustachian tube","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",381877,"Dysfunction of eustachian tube","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",381877,"Dysfunction of eustachian tube","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",381877,"Dysfunction of eustachian tube","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",381877,"Dysfunction of eustachian tube","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",381877,"Dysfunction of eustachian tube","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",381877,"Dysfunction of eustachian tube","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",74725,"Displacement of cervical intervertebral disc without myelopathy","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197607,"Excessive and frequent menstruation","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197607,"Excessive and frequent menstruation","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197607,"Excessive and frequent menstruation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197607,"Excessive and frequent menstruation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197607,"Excessive and frequent menstruation","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197607,"Excessive and frequent menstruation","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197607,"Excessive and frequent menstruation","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197607,"Excessive and frequent menstruation","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197607,"Excessive and frequent menstruation","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197607,"Excessive and frequent menstruation","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197607,"Excessive and frequent menstruation","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",45768910,"Uncomplicated asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",45768910,"Uncomplicated asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",45768910,"Uncomplicated asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",45768910,"Uncomplicated asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",45768910,"Uncomplicated asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",45768910,"Uncomplicated asthma","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",45768910,"Uncomplicated asthma","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",45768910,"Uncomplicated asthma","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",45768910,"Uncomplicated asthma","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",45768910,"Uncomplicated asthma","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",45768910,"Uncomplicated asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",377910,"Deviated nasal septum","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",377910,"Deviated nasal septum","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",377910,"Deviated nasal septum","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",377910,"Deviated nasal septum","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",377910,"Deviated nasal septum","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",377910,"Deviated nasal septum","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",377910,"Deviated nasal septum","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",377910,"Deviated nasal septum","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",377910,"Deviated nasal septum","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",377910,"Deviated nasal septum","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",377910,"Deviated nasal septum","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4308509,"Impaired fasting glycaemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4308509,"Impaired fasting glycaemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4308509,"Impaired fasting glycaemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4308509,"Impaired fasting glycaemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4308509,"Impaired fasting glycaemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4308509,"Impaired fasting glycaemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4308509,"Impaired fasting glycaemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4308509,"Impaired fasting glycaemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4308509,"Impaired fasting glycaemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4308509,"Impaired fasting glycaemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4308509,"Impaired fasting glycaemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",136773,"Rosacea","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",136773,"Rosacea","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",136773,"Rosacea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",136773,"Rosacea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",136773,"Rosacea","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",136773,"Rosacea","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",136773,"Rosacea","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",136773,"Rosacea","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",136773,"Rosacea","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",136773,"Rosacea","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",136773,"Rosacea","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",444367,"Cholelithiasis without obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",444367,"Cholelithiasis without obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",444367,"Cholelithiasis without obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",444367,"Cholelithiasis without obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",444367,"Cholelithiasis without obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",444367,"Cholelithiasis without obstruction","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",444367,"Cholelithiasis without obstruction","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",444367,"Cholelithiasis without obstruction","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",444367,"Cholelithiasis without obstruction","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",444367,"Cholelithiasis without obstruction","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",444367,"Cholelithiasis without obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201072,"Benign prostatic hypertrophy without outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4209423,"Nicotine dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4209423,"Nicotine dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4209423,"Nicotine dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4209423,"Nicotine dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4209423,"Nicotine dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4209423,"Nicotine dependence","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4209423,"Nicotine dependence","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4209423,"Nicotine dependence","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4209423,"Nicotine dependence","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4209423,"Nicotine dependence","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4209423,"Nicotine dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",435515,"Hypo-osmolality and or hyponatremia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",198400,"Hemangioma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",379805,"Myopia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",379805,"Myopia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",379805,"Myopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",379805,"Myopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",379805,"Myopia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",379805,"Myopia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",379805,"Myopia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",379805,"Myopia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",379805,"Myopia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",379805,"Myopia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",379805,"Myopia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",437851,"Open angle with borderline intraocular pressure","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",437851,"Open angle with borderline intraocular pressure","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",437851,"Open angle with borderline intraocular pressure","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",437851,"Open angle with borderline intraocular pressure","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",437851,"Open angle with borderline intraocular pressure","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",437851,"Open angle with borderline intraocular pressure","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",437851,"Open angle with borderline intraocular pressure","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",437851,"Open angle with borderline intraocular pressure","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",437851,"Open angle with borderline intraocular pressure","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",437851,"Open angle with borderline intraocular pressure","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",437851,"Open angle with borderline intraocular pressure","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201418,"Flatulence, eructation and gas pain","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201418,"Flatulence, eructation and gas pain","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201418,"Flatulence, eructation and gas pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201418,"Flatulence, eructation and gas pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201418,"Flatulence, eructation and gas pain","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201418,"Flatulence, eructation and gas pain","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201418,"Flatulence, eructation and gas pain","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201418,"Flatulence, eructation and gas pain","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201418,"Flatulence, eructation and gas pain","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201418,"Flatulence, eructation and gas pain","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201418,"Flatulence, eructation and gas pain","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197672,"Urinary incontinence","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197672,"Urinary incontinence","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197672,"Urinary incontinence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197672,"Urinary incontinence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197672,"Urinary incontinence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197672,"Urinary incontinence","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197672,"Urinary incontinence","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197672,"Urinary incontinence","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197672,"Urinary incontinence","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197672,"Urinary incontinence","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197672,"Urinary incontinence","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",199866,"Acute gastritis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",199866,"Acute gastritis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",199866,"Acute gastritis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",199866,"Acute gastritis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",199866,"Acute gastritis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",199866,"Acute gastritis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",199866,"Acute gastritis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",199866,"Acute gastritis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",199866,"Acute gastritis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",199866,"Acute gastritis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",199866,"Acute gastritis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",316127,"Vitreous opacities","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",316127,"Vitreous opacities","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",316127,"Vitreous opacities","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",316127,"Vitreous opacities","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",316127,"Vitreous opacities","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",316127,"Vitreous opacities","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",316127,"Vitreous opacities","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",316127,"Vitreous opacities","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",316127,"Vitreous opacities","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",316127,"Vitreous opacities","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",316127,"Vitreous opacities","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",136497,"Scar conditions and fibrosis of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",136497,"Scar conditions and fibrosis of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",136497,"Scar conditions and fibrosis of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",136497,"Scar conditions and fibrosis of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",136497,"Scar conditions and fibrosis of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",136497,"Scar conditions and fibrosis of skin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",136497,"Scar conditions and fibrosis of skin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",136497,"Scar conditions and fibrosis of skin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",136497,"Scar conditions and fibrosis of skin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",136497,"Scar conditions and fibrosis of skin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",136497,"Scar conditions and fibrosis of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4033837,"Melanocytic nevus of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4033837,"Melanocytic nevus of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4033837,"Melanocytic nevus of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4033837,"Melanocytic nevus of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4033837,"Melanocytic nevus of trunk","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4033837,"Melanocytic nevus of trunk","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4033837,"Melanocytic nevus of trunk","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4033837,"Melanocytic nevus of trunk","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4033837,"Melanocytic nevus of trunk","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4033837,"Melanocytic nevus of trunk","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4033837,"Melanocytic nevus of trunk","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",432883,"Recurrent major depressive episodes, moderate","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",432883,"Recurrent major depressive episodes, moderate","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",432883,"Recurrent major depressive episodes, moderate","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",432883,"Recurrent major depressive episodes, moderate","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",432883,"Recurrent major depressive episodes, moderate","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",432883,"Recurrent major depressive episodes, moderate","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",432883,"Recurrent major depressive episodes, moderate","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",432883,"Recurrent major depressive episodes, moderate","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",432883,"Recurrent major depressive episodes, moderate","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",432883,"Recurrent major depressive episodes, moderate","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",432883,"Recurrent major depressive episodes, moderate","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",321596,"Peripheral venous insufficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",321596,"Peripheral venous insufficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",321596,"Peripheral venous insufficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",321596,"Peripheral venous insufficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",321596,"Peripheral venous insufficiency","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",321596,"Peripheral venous insufficiency","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",321596,"Peripheral venous insufficiency","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",321596,"Peripheral venous insufficiency","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",321596,"Peripheral venous insufficiency","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",321596,"Peripheral venous insufficiency","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",321596,"Peripheral venous insufficiency","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",443597,"Chronic kidney disease stage 3","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",443597,"Chronic kidney disease stage 3","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",443597,"Chronic kidney disease stage 3","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",443597,"Chronic kidney disease stage 3","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",443597,"Chronic kidney disease stage 3","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",443597,"Chronic kidney disease stage 3","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",443597,"Chronic kidney disease stage 3","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",443597,"Chronic kidney disease stage 3","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",443597,"Chronic kidney disease stage 3","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",443597,"Chronic kidney disease stage 3","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",443597,"Chronic kidney disease stage 3","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",433440,"Dysthymia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",433440,"Dysthymia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",433440,"Dysthymia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",433440,"Dysthymia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",433440,"Dysthymia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",433440,"Dysthymia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",433440,"Dysthymia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",433440,"Dysthymia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",433440,"Dysthymia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",433440,"Dysthymia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",433440,"Dysthymia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",438409,"Attention deficit hyperactivity disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",438409,"Attention deficit hyperactivity disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",438409,"Attention deficit hyperactivity disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",438409,"Attention deficit hyperactivity disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",438409,"Attention deficit hyperactivity disorder","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",438409,"Attention deficit hyperactivity disorder","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",438409,"Attention deficit hyperactivity disorder","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",438409,"Attention deficit hyperactivity disorder","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",438409,"Attention deficit hyperactivity disorder","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",438409,"Attention deficit hyperactivity disorder","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",438409,"Attention deficit hyperactivity disorder","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4172432,"Hyperpigmentation of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4172432,"Hyperpigmentation of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4172432,"Hyperpigmentation of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4172432,"Hyperpigmentation of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4172432,"Hyperpigmentation of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4172432,"Hyperpigmentation of skin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4172432,"Hyperpigmentation of skin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4172432,"Hyperpigmentation of skin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4172432,"Hyperpigmentation of skin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4172432,"Hyperpigmentation of skin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4172432,"Hyperpigmentation of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",26662,"Testicular hypofunction","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",26662,"Testicular hypofunction","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",26662,"Testicular hypofunction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",26662,"Testicular hypofunction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",26662,"Testicular hypofunction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",26662,"Testicular hypofunction","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",26662,"Testicular hypofunction","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",26662,"Testicular hypofunction","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",26662,"Testicular hypofunction","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",26662,"Testicular hypofunction","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",26662,"Testicular hypofunction","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",76161,"Impotence of organic origin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",76161,"Impotence of organic origin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",76161,"Impotence of organic origin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",76161,"Impotence of organic origin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",76161,"Impotence of organic origin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",76161,"Impotence of organic origin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",76161,"Impotence of organic origin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",76161,"Impotence of organic origin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",76161,"Impotence of organic origin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",76161,"Impotence of organic origin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",76161,"Impotence of organic origin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",381292,"Chronic allergic conjunctivitis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",381292,"Chronic allergic conjunctivitis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",381292,"Chronic allergic conjunctivitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",381292,"Chronic allergic conjunctivitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",381292,"Chronic allergic conjunctivitis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",381292,"Chronic allergic conjunctivitis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",381292,"Chronic allergic conjunctivitis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",381292,"Chronic allergic conjunctivitis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",381292,"Chronic allergic conjunctivitis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",381292,"Chronic allergic conjunctivitis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",381292,"Chronic allergic conjunctivitis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",257004,"Acute exacerbation of chronic obstructive airways disease","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",376065,"Neurologic disorder associated with type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",432738,"Chronic fatigue syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",432738,"Chronic fatigue syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",432738,"Chronic fatigue syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",432738,"Chronic fatigue syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",432738,"Chronic fatigue syndrome","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",432738,"Chronic fatigue syndrome","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",432738,"Chronic fatigue syndrome","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",432738,"Chronic fatigue syndrome","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",432738,"Chronic fatigue syndrome","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",432738,"Chronic fatigue syndrome","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",432738,"Chronic fatigue syndrome","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",433811,"Hydronephrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",433811,"Hydronephrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",433811,"Hydronephrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",433811,"Hydronephrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",433811,"Hydronephrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",433811,"Hydronephrosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",433811,"Hydronephrosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",433811,"Hydronephrosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",433811,"Hydronephrosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",433811,"Hydronephrosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",433811,"Hydronephrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",201254,"Type 1 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",201254,"Type 1 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",201254,"Type 1 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",201254,"Type 1 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",201254,"Type 1 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",201254,"Type 1 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",201254,"Type 1 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",201254,"Type 1 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",201254,"Type 1 diabetes mellitus","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",201254,"Type 1 diabetes mellitus","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",201254,"Type 1 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",440129,"Hypertrophy of nasal turbinates","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",440129,"Hypertrophy of nasal turbinates","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",440129,"Hypertrophy of nasal turbinates","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",440129,"Hypertrophy of nasal turbinates","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",440129,"Hypertrophy of nasal turbinates","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",440129,"Hypertrophy of nasal turbinates","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",440129,"Hypertrophy of nasal turbinates","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",440129,"Hypertrophy of nasal turbinates","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",440129,"Hypertrophy of nasal turbinates","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",440129,"Hypertrophy of nasal turbinates","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",440129,"Hypertrophy of nasal turbinates","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436118,"After-cataract with vision obscured","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436118,"After-cataract with vision obscured","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436118,"After-cataract with vision obscured","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436118,"After-cataract with vision obscured","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436118,"After-cataract with vision obscured","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436118,"After-cataract with vision obscured","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436118,"After-cataract with vision obscured","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436118,"After-cataract with vision obscured","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436118,"After-cataract with vision obscured","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436118,"After-cataract with vision obscured","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436118,"After-cataract with vision obscured","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",77139,"Open wound of finger without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",77139,"Open wound of finger without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",77139,"Open wound of finger without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",77139,"Open wound of finger without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",77139,"Open wound of finger without complication","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",77139,"Open wound of finger without complication","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",77139,"Open wound of finger without complication","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",77139,"Open wound of finger without complication","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",77139,"Open wound of finger without complication","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",77139,"Open wound of finger without complication","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",77139,"Open wound of finger without complication","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",261325,"Pulmonary emphysema","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",261325,"Pulmonary emphysema","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",261325,"Pulmonary emphysema","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",261325,"Pulmonary emphysema","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",261325,"Pulmonary emphysema","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",261325,"Pulmonary emphysema","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",261325,"Pulmonary emphysema","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",261325,"Pulmonary emphysema","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",261325,"Pulmonary emphysema","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",261325,"Pulmonary emphysema","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",261325,"Pulmonary emphysema","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",138384,"Acquired hypothyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",138384,"Acquired hypothyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",138384,"Acquired hypothyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",138384,"Acquired hypothyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",138384,"Acquired hypothyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",138384,"Acquired hypothyroidism","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",138384,"Acquired hypothyroidism","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",138384,"Acquired hypothyroidism","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",138384,"Acquired hypothyroidism","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",138384,"Acquired hypothyroidism","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",138384,"Acquired hypothyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",443211,"Benign prostatic hypertrophy with outflow obstruction","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",381295,"Age-related cataract","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",381295,"Age-related cataract","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",381295,"Age-related cataract","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",381295,"Age-related cataract","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",381295,"Age-related cataract","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",381295,"Age-related cataract","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",381295,"Age-related cataract","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",381295,"Age-related cataract","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",381295,"Age-related cataract","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",381295,"Age-related cataract","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",381295,"Age-related cataract","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",318556,"Epistaxis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",318556,"Epistaxis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",318556,"Epistaxis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",318556,"Epistaxis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",318556,"Epistaxis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",318556,"Epistaxis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",318556,"Epistaxis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",318556,"Epistaxis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",318556,"Epistaxis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",318556,"Epistaxis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",318556,"Epistaxis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",377575,"Tinnitus","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",377575,"Tinnitus","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",377575,"Tinnitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",377575,"Tinnitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",377575,"Tinnitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",377575,"Tinnitus","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",377575,"Tinnitus","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",377575,"Tinnitus","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",377575,"Tinnitus","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",377575,"Tinnitus","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",377575,"Tinnitus","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",434610,"Hyperkalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",434610,"Hyperkalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",434610,"Hyperkalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",434610,"Hyperkalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",434610,"Hyperkalemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",434610,"Hyperkalemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",434610,"Hyperkalemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",434610,"Hyperkalemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",434610,"Hyperkalemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",434610,"Hyperkalemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",434610,"Hyperkalemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",137951,"Acquired keratoderma","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",137951,"Acquired keratoderma","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",137951,"Acquired keratoderma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",137951,"Acquired keratoderma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",137951,"Acquired keratoderma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",137951,"Acquired keratoderma","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",137951,"Acquired keratoderma","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",137951,"Acquired keratoderma","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",137951,"Acquired keratoderma","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",137951,"Acquired keratoderma","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",137951,"Acquired keratoderma","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",72715,"Exostosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",72715,"Exostosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",72715,"Exostosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",72715,"Exostosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",72715,"Exostosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",72715,"Exostosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",72715,"Exostosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",72715,"Exostosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",72715,"Exostosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",72715,"Exostosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",72715,"Exostosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4110815,"Sensorineural hearing loss, bilateral","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",198803,"Benign prostatic hyperplasia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",198803,"Benign prostatic hyperplasia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",198803,"Benign prostatic hyperplasia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",198803,"Benign prostatic hyperplasia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",198803,"Benign prostatic hyperplasia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",198803,"Benign prostatic hyperplasia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",198803,"Benign prostatic hyperplasia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",198803,"Benign prostatic hyperplasia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",198803,"Benign prostatic hyperplasia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",198803,"Benign prostatic hyperplasia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",198803,"Benign prostatic hyperplasia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",312950,"IgE-mediated allergic asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",312950,"IgE-mediated allergic asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",312950,"IgE-mediated allergic asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",312950,"IgE-mediated allergic asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",312950,"IgE-mediated allergic asthma","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",312950,"IgE-mediated allergic asthma","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",312950,"IgE-mediated allergic asthma","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",312950,"IgE-mediated allergic asthma","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",312950,"IgE-mediated allergic asthma","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",312950,"IgE-mediated allergic asthma","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",312950,"IgE-mediated allergic asthma","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",194686,"Acquired renal cystic disease","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",194686,"Acquired renal cystic disease","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",194686,"Acquired renal cystic disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",194686,"Acquired renal cystic disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",194686,"Acquired renal cystic disease","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",194686,"Acquired renal cystic disease","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",194686,"Acquired renal cystic disease","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",194686,"Acquired renal cystic disease","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",194686,"Acquired renal cystic disease","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",194686,"Acquired renal cystic disease","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",194686,"Acquired renal cystic disease","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",192450,"Retention of urine","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",192450,"Retention of urine","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",192450,"Retention of urine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",192450,"Retention of urine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",192450,"Retention of urine","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",192450,"Retention of urine","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",192450,"Retention of urine","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",192450,"Retention of urine","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",192450,"Retention of urine","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",192450,"Retention of urine","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",192450,"Retention of urine","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4305080,"Abnormal breathing","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4305080,"Abnormal breathing","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4305080,"Abnormal breathing","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4305080,"Abnormal breathing","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4305080,"Abnormal breathing","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4305080,"Abnormal breathing","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4305080,"Abnormal breathing","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4305080,"Abnormal breathing","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4305080,"Abnormal breathing","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4305080,"Abnormal breathing","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4305080,"Abnormal breathing","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",200528,"Ascites","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",200528,"Ascites","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",200528,"Ascites","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",200528,"Ascites","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",200528,"Ascites","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",200528,"Ascites","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",200528,"Ascites","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",200528,"Ascites","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",200528,"Ascites","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",200528,"Ascites","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",200528,"Ascites","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",73754,"Restless legs","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",73754,"Restless legs","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",73754,"Restless legs","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",73754,"Restless legs","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",73754,"Restless legs","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",73754,"Restless legs","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",73754,"Restless legs","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",73754,"Restless legs","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",73754,"Restless legs","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",73754,"Restless legs","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",73754,"Restless legs","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4168217,"Generalized hyperhidrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4168217,"Generalized hyperhidrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4168217,"Generalized hyperhidrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4168217,"Generalized hyperhidrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4168217,"Generalized hyperhidrosis","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4168217,"Generalized hyperhidrosis","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4168217,"Generalized hyperhidrosis","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4168217,"Generalized hyperhidrosis","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4168217,"Generalized hyperhidrosis","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4168217,"Generalized hyperhidrosis","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4168217,"Generalized hyperhidrosis","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",439147,"Amnesia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",439147,"Amnesia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",439147,"Amnesia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",439147,"Amnesia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",439147,"Amnesia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",439147,"Amnesia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",439147,"Amnesia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",439147,"Amnesia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",439147,"Amnesia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",439147,"Amnesia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",439147,"Amnesia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436375,"Hypovolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436375,"Hypovolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436375,"Hypovolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436375,"Hypovolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436375,"Hypovolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436375,"Hypovolemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436375,"Hypovolemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436375,"Hypovolemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436375,"Hypovolemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436375,"Hypovolemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436375,"Hypovolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",432730,"Difficulty speaking","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",432730,"Difficulty speaking","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",432730,"Difficulty speaking","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",432730,"Difficulty speaking","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",432730,"Difficulty speaking","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",432730,"Difficulty speaking","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",432730,"Difficulty speaking","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",432730,"Difficulty speaking","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",432730,"Difficulty speaking","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",432730,"Difficulty speaking","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",432730,"Difficulty speaking","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",432798,"Mechanical complication of internal orthopedic device, implant AND/OR graft","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",433163,"Deficiency of macronutrients","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",433163,"Deficiency of macronutrients","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",433163,"Deficiency of macronutrients","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",433163,"Deficiency of macronutrients","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",433163,"Deficiency of macronutrients","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",433163,"Deficiency of macronutrients","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",433163,"Deficiency of macronutrients","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",433163,"Deficiency of macronutrients","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",433163,"Deficiency of macronutrients","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",433163,"Deficiency of macronutrients","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",433163,"Deficiency of macronutrients","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",438120,"Opioid dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",438120,"Opioid dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",438120,"Opioid dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",438120,"Opioid dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",438120,"Opioid dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",438120,"Opioid dependence","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",438120,"Opioid dependence","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",438120,"Opioid dependence","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",438120,"Opioid dependence","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",438120,"Opioid dependence","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",438120,"Opioid dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",141375,"Hypertrophic condition of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",141375,"Hypertrophic condition of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",141375,"Hypertrophic condition of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",141375,"Hypertrophic condition of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",141375,"Hypertrophic condition of skin","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",141375,"Hypertrophic condition of skin","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",141375,"Hypertrophic condition of skin","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",141375,"Hypertrophic condition of skin","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",141375,"Hypertrophic condition of skin","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",141375,"Hypertrophic condition of skin","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",141375,"Hypertrophic condition of skin","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197911,"Hernia of anterior abdominal wall without obstruction AND without gangrene","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4211231,"Panic disorder without agoraphobia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4211231,"Panic disorder without agoraphobia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4211231,"Panic disorder without agoraphobia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4211231,"Panic disorder without agoraphobia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4211231,"Panic disorder without agoraphobia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4211231,"Panic disorder without agoraphobia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4211231,"Panic disorder without agoraphobia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4211231,"Panic disorder without agoraphobia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4211231,"Panic disorder without agoraphobia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4211231,"Panic disorder without agoraphobia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4211231,"Panic disorder without agoraphobia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4103703,"Melena","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4103703,"Melena","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4103703,"Melena","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4103703,"Melena","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4103703,"Melena","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4103703,"Melena","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4103703,"Melena","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4103703,"Melena","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4103703,"Melena","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4103703,"Melena","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4103703,"Melena","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",72737,"Microcalcifications of the breast","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",72737,"Microcalcifications of the breast","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",72737,"Microcalcifications of the breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",72737,"Microcalcifications of the breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",72737,"Microcalcifications of the breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",72737,"Microcalcifications of the breast","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",72737,"Microcalcifications of the breast","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",72737,"Microcalcifications of the breast","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",72737,"Microcalcifications of the breast","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",72737,"Microcalcifications of the breast","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",72737,"Microcalcifications of the breast","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",435511,"Hypercalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",435511,"Hypercalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",435511,"Hypercalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",435511,"Hypercalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",435511,"Hypercalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",435511,"Hypercalcemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",435511,"Hypercalcemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",435511,"Hypercalcemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",435511,"Hypercalcemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",435511,"Hypercalcemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",435511,"Hypercalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4002818,"Spasm of back muscles","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4002818,"Spasm of back muscles","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4002818,"Spasm of back muscles","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4002818,"Spasm of back muscles","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4002818,"Spasm of back muscles","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4002818,"Spasm of back muscles","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4002818,"Spasm of back muscles","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4002818,"Spasm of back muscles","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4002818,"Spasm of back muscles","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4002818,"Spasm of back muscles","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4002818,"Spasm of back muscles","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",197006,"Residual hemorrhoidal skin tags","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",197006,"Residual hemorrhoidal skin tags","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",197006,"Residual hemorrhoidal skin tags","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",197006,"Residual hemorrhoidal skin tags","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",197006,"Residual hemorrhoidal skin tags","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",197006,"Residual hemorrhoidal skin tags","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",197006,"Residual hemorrhoidal skin tags","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",197006,"Residual hemorrhoidal skin tags","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",197006,"Residual hemorrhoidal skin tags","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",197006,"Residual hemorrhoidal skin tags","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",197006,"Residual hemorrhoidal skin tags","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436940,"Metabolic syndrome X","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436940,"Metabolic syndrome X","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436940,"Metabolic syndrome X","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436940,"Metabolic syndrome X","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436940,"Metabolic syndrome X","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436940,"Metabolic syndrome X","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436940,"Metabolic syndrome X","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436940,"Metabolic syndrome X","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436940,"Metabolic syndrome X","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436940,"Metabolic syndrome X","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436940,"Metabolic syndrome X","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",443731,"Renal disorder due to type 2 diabetes mellitus","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",433753,"Alcohol abuse","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",433753,"Alcohol abuse","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",433753,"Alcohol abuse","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",433753,"Alcohol abuse","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",433753,"Alcohol abuse","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",433753,"Alcohol abuse","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",433753,"Alcohol abuse","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",433753,"Alcohol abuse","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",433753,"Alcohol abuse","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",433753,"Alcohol abuse","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",433753,"Alcohol abuse","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4311591,"Cramp in limb","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4311591,"Cramp in limb","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4311591,"Cramp in limb","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4311591,"Cramp in limb","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4311591,"Cramp in limb","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4311591,"Cramp in limb","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4311591,"Cramp in limb","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4311591,"Cramp in limb","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4311591,"Cramp in limb","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4311591,"Cramp in limb","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4311591,"Cramp in limb","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",376382,"Tension-type headache","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",376382,"Tension-type headache","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",376382,"Tension-type headache","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",376382,"Tension-type headache","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",376382,"Tension-type headache","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",376382,"Tension-type headache","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",376382,"Tension-type headache","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",376382,"Tension-type headache","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",376382,"Tension-type headache","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",376382,"Tension-type headache","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",376382,"Tension-type headache","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",196456,"Gallstone","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",196456,"Gallstone","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",196456,"Gallstone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",196456,"Gallstone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",196456,"Gallstone","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",196456,"Gallstone","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",196456,"Gallstone","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",196456,"Gallstone","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",196456,"Gallstone","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",196456,"Gallstone","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",196456,"Gallstone","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",198101,"Lipoma of skin and subcutaneous tissue","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",441417,"Incoordination","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",441417,"Incoordination","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",441417,"Incoordination","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",441417,"Incoordination","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",441417,"Incoordination","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",441417,"Incoordination","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",441417,"Incoordination","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",441417,"Incoordination","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",441417,"Incoordination","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",441417,"Incoordination","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",441417,"Incoordination","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",436246,"Reduced libido","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",436246,"Reduced libido","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",436246,"Reduced libido","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",436246,"Reduced libido","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",436246,"Reduced libido","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",436246,"Reduced libido","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",436246,"Reduced libido","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",436246,"Reduced libido","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",436246,"Reduced libido","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",436246,"Reduced libido","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",436246,"Reduced libido","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4088920,"Uterus absent","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4088920,"Uterus absent","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4088920,"Uterus absent","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4088920,"Uterus absent","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4088920,"Uterus absent","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4088920,"Uterus absent","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4088920,"Uterus absent","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4088920,"Uterus absent","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4088920,"Uterus absent","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4088920,"Uterus absent","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4088920,"Uterus absent","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",78474,"Hypertrophy of breast","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",78474,"Hypertrophy of breast","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",78474,"Hypertrophy of breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",78474,"Hypertrophy of breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",78474,"Hypertrophy of breast","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",78474,"Hypertrophy of breast","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",78474,"Hypertrophy of breast","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",78474,"Hypertrophy of breast","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",78474,"Hypertrophy of breast","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",78474,"Hypertrophy of breast","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",78474,"Hypertrophy of breast","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",435510,"Hypocalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",435510,"Hypocalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",435510,"Hypocalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",435510,"Hypocalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",435510,"Hypocalcemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",435510,"Hypocalcemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",435510,"Hypocalcemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",435510,"Hypocalcemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",435510,"Hypocalcemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",435510,"Hypocalcemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",435510,"Hypocalcemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",73575,"Deformity of toe","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",73575,"Deformity of toe","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",73575,"Deformity of toe","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",73575,"Deformity of toe","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",73575,"Deformity of toe","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",73575,"Deformity of toe","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",73575,"Deformity of toe","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",73575,"Deformity of toe","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",73575,"Deformity of toe","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",73575,"Deformity of toe","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",73575,"Deformity of toe","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",136661,"Non-toxic nodular goiter","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",136661,"Non-toxic nodular goiter","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",136661,"Non-toxic nodular goiter","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",136661,"Non-toxic nodular goiter","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",136661,"Non-toxic nodular goiter","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",136661,"Non-toxic nodular goiter","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",136661,"Non-toxic nodular goiter","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",136661,"Non-toxic nodular goiter","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",136661,"Non-toxic nodular goiter","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",136661,"Non-toxic nodular goiter","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",136661,"Non-toxic nodular goiter","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",435243,"Alcohol dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",435243,"Alcohol dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",435243,"Alcohol dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",435243,"Alcohol dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",435243,"Alcohol dependence","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",435243,"Alcohol dependence","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",435243,"Alcohol dependence","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",435243,"Alcohol dependence","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",435243,"Alcohol dependence","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",435243,"Alcohol dependence","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",435243,"Alcohol dependence","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",195603,"Vulval and/or perineal noninflammatory disorders","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",78162,"Peripheral vertigo","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",78162,"Peripheral vertigo","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",78162,"Peripheral vertigo","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",78162,"Peripheral vertigo","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",78162,"Peripheral vertigo","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",78162,"Peripheral vertigo","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",78162,"Peripheral vertigo","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",78162,"Peripheral vertigo","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",78162,"Peripheral vertigo","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",78162,"Peripheral vertigo","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",78162,"Peripheral vertigo","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4084229,"Primary gout","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4084229,"Primary gout","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4084229,"Primary gout","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4084229,"Primary gout","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4084229,"Primary gout","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4084229,"Primary gout","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4084229,"Primary gout","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4084229,"Primary gout","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4084229,"Primary gout","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4084229,"Primary gout","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4084229,"Primary gout","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",434004,"Hypervolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",434004,"Hypervolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",434004,"Hypervolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",434004,"Hypervolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",434004,"Hypervolemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",434004,"Hypervolemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",434004,"Hypervolemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",434004,"Hypervolemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",434004,"Hypervolemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",434004,"Hypervolemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",434004,"Hypervolemia","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",133729,"Hyperparathyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",133729,"Hyperparathyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",133729,"Hyperparathyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",133729,"Hyperparathyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",133729,"Hyperparathyroidism","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",133729,"Hyperparathyroidism","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",133729,"Hyperparathyroidism","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",133729,"Hyperparathyroidism","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",133729,"Hyperparathyroidism","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",133729,"Hyperparathyroidism","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",133729,"Hyperparathyroidism","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",193255,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament","Outcome"
6593,"Tofacitinib, satisfying trial",6609,"Adalimumab, satisfying trial",4098604,"Hypomagnesemia","Outcome"
6593,"Tofacitinib, satisfying trial",6610,"Etanercept, satisfying trial",4098604,"Hypomagnesemia","Outcome"
6593,"Tofacitinib, satisfying trial",6611,"Adalimumab or etanercept, satisfying trial",4098604,"Hypomagnesemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6612,"Adalimumab, satisfying trial without methotrexate",4098604,"Hypomagnesemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6614,"Etanercept, satisfying trial without methotrexate",4098604,"Hypomagnesemia","Outcome"
6607,"Tofacitinib, satisfying trial without methotrexate",6616,"Adalimumab or etanercept, satisfying trial without methotrexate",4098604,"Hypomagnesemia","Outcome"
6608,"Tofacitinib, real-world population",6613,"Adalimumab real-world population",4098604,"Hypomagnesemia","Outcome"
6608,"Tofacitinib, real-world population",6615,"Etanercept real world population",4098604,"Hypomagnesemia","Outcome"
6608,"Tofacitinib, real-world population",6617,"Adalimumab or etanercept real world population",4098604,"Hypomagnesemia","Outcome"
6609,"Adalimumab, satisfying trial",6610,"Etanercept, satisfying trial",4098604,"Hypomagnesemia","Outcome"
6613,"Adalimumab, real-world population",6615,"Etanercept, real world population",4098604,"Hypomagnesemia","Outcome"
